Lixte Biotechnology Holdings (DB:8640) - Prezzo delle azioni, notizie e analisi

8640 Panoramica delle azioni

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Maggiori dettagli

8640 analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Analisi del rischio

Gli utili sono diminuiti del 28.3% all'anno negli ultimi 5 anni

Non ha una capitalizzazione di mercato significativa ( €6M )

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Le azioni sono altamente illiquide

+ 2 più rischi

Lixte Biotechnology Holdings, Inc. Concorrenti

co.don

XTRA:CNW

€6.5m

bioXXmed

XTRA:T5O

€1.4m

Medigene

XTRA:MDG1

€17.4m

4SC

DB:VSC

€50.2m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Lixte Biotechnology Holdings
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.63
Massimo di 52 settimane	US$15.00
Minimo di 52 settimane	US$4.12
Beta	-0.44
1Variazione di 1 mese	0%
Variazione a 3 mesi	-89.75%
Variazione di 1 anno	-90.74%
3Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	-97.99%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	8640	DE Biotechs	DE Mercato
7D	0%	-1.1%	1.1%
1Y	-90.7%	-18.8%	7.2%

Ritorno vs Industria: 8640 ha avuto una performance inferiore rispetto al German Biotechs che ha registrato un rendimento -18.8 % nell'ultimo anno.

Rendimento vs Mercato: 8640 ha avuto una performance inferiore al mercato German che ha registrato un rendimento 7.2 % nell'ultimo anno.

Volatilità dei prezzi

Is 8640's price volatile compared to industry and market?
8640 volatility
8640 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: Il prezzo delle azioni di 8640 è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di 8640 nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2005	4	John Kovach	lixte.com

Lixte Biotechnology Holdings, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Lixte Biotechnology Holdings con la sua capitalizzazione di mercato?
8640 statistiche fondamentali
Capitalizzazione di mercato	€5.24m
Guadagni(TTM)	-€5.70m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-0.9x

Rapporto P/E

8640 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
8640 Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$6.15m
Guadagni	-US$6.15m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-2.73
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato 8640 nel lungo periodo?

Vedi performance storica e confronto

8640 Panoramica delle azioni

Analisi del rischio

Lixte Biotechnology Holdings, Inc. Concorrenti

XTRA:CNW

€6.5m

XTRA:T5O

€1.4m

XTRA:MDG1

€17.4m

DB:VSC

€50.2m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Dec 19, 2024

Lixte Biotechnology Holdings Receives an Extension Through February 18, 2025 to Regain Compliance with the Stockholders’ Equity Requirement

First Patient Dosed with Lixte Biotechnology Holdings, Inc.’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Lixte Biotechnology Holdings, Inc. Reports Findings Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LIXTE Biotechnology Holdings, Inc. Announces Executive Changes

Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal

Recent updates

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Dec 19, 2024

Lixte Biotechnology Holdings Receives an Extension Through February 18, 2025 to Regain Compliance with the Stockholders’ Equity Requirement

First Patient Dosed with Lixte Biotechnology Holdings, Inc.’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Lixte Biotechnology Holdings, Inc. Reports Findings Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LIXTE Biotechnology Holdings, Inc. Announces Executive Changes

Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal

LIXTE Biotechnology Holdings, Inc. Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Nov 27, 2023

Lixte Biotechnology Holdings, Inc. Announces Chief Executive Officer Changes

LIXTE Biotechnology Holdings, Inc. Announces Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

LIXTE Biotechnology Holdings, Inc. Announces the Enrollment of the First Patient in the Phase 1b Portion of the Phase 1b/2 Protocol

LIXTE Biotechnology Announces 1-for-10 Reverse Stock Split to Bring it into Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Lixte Biotechnology Holdings, Inc. Announces Recently Published Independent Research Reveals New Mechanisms

Lixte Biotechnology Holdings, Inc. Promotes Eric Forman to Vice President and Chief Operating Officer

LIXTE Biotechnology Holdings, Inc. Announces Spanish Agency for Medicines and Health Products Authorized Phase 1b/Randomized Phase 2 Study of LB-100

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Oct 07, 2022

Lixte Biotechnology Holdings, Inc. Appoints Bastiaan Van Der Baan as Independent Director

Lixte Biotechnology Holdings, Inc. Appoints Bas Van Der Baan to Its Board of Directors

Lixte Biotechnology Holdings, Inc. Announces Appointment of Professor René Bernards to its Board of Directors

Philip Palmedo Not to Stand for Re-Election as Director of Lixte Biotechnology Holdings, Inc

Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors

Lixte Biotechnology Holdings, Inc. Announces Enrollment Has Resumed in National Cancer Institute’s Trial to Determine Ability of Lixte Compound LB-100 to Enter Recurrent, Malignant Brain Tumors

LixteBiotechnology Holdings, Inc.'s Pre-Clinical Research Demonstrates Inhibition of Protein Phosphatase 2A with LB-100 Combined with the Experimental Drug, Vosoritide

Lixte Biotechnology Holdings, Inc.(NasdaqCM:LIXT) dropped from Russell 3000E Value Index

Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer

Independent Director has left the company